Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
On logistic regression analyses, glucose, AST, bilirubin, hemoglobin levels, and HCV infection (adjusted odds ratio [aORs]: 1.01, 1.02, 3.04, and 9.73, respectively) were associated with CD163.
|
31797394 |
2020 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnostic performance of AFP/(AST*ALT) could be verified in hepatitis B virus (HBV)- or hepatitis C virus (HCV)-associated HCC patients as well.
|
31027143 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In HCV-negative recipients, allografts with >15% Sd-MaS have significantly reduced graft survival and show low ATP and higher AST peaks in the immediate posttransplant period.
|
31187028 |
2019 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to compare the diagnostic abilities of Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA-M2BP), Enhanced liver fibrosis (ELF) score, Fibrosis-4 index, and AST to platelet ratio index (APRI) based on histopathological analysis of liver biopsy samples, from patients with positive Hepatitis C Virus (HCV) infection.
|
30208564 |
2018 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
At baseline, presence of PLNE was significantly associated with a lower serum HCV-RNA level (P = .03), a higher serum AST level (P = .004) and a higher ALT level (P < .001) after adjustment for sex and age.
|
29091333 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
TnC and AST together were significantly better indicators of cirrhosis in patients with active HCV infection than other markers tested.
|
29330728 |
2018 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The predictive value of the AST to Platelet Ratio Index (APRI) score, originally developed for fibrosis assessment in hepatitis C virus (HCV) patients, is much less known in the context of NAFLD patients.
|
28572039 |
2017 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results showed decreased levels of ALT and AST (<i>p</i> = 0.00), demonstrating less liver destruction in ESRD HCV<sup>+</sup> patients in comparison to HCV<sup>+</sup> patients.
|
28487598 |
2017 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
A significant increase in AST activity was observed in the seronegative and OCI groups and in ALT and AST in HCV-seronegative or OCI and negative HCV patients (p ≤ 0.05).
|
27665588 |
2017 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum AST and ALT level were likely to increase with HCV RNA level, although no significance was observed.
|
24709894 |
2014 |
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additionally CC(rs12979860) among HCV genotype 3 infected patients was associated with higher liver stiffness values (P = 0.004), and higher AST to platelet ratio index (APRI; p = 0.02) as compared to carriers of the T allele.
|
24244641 |
2013 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical, virological, histological characteristics, and biochemical tests including; liver function tests (ALT and AST), prothrombin time (PT), alpha fetoprotein (AFP), complete blood picture (CBC), and hGH were monitored in hepatitis C genotype-4 infected patients before and after interferon therapy, and healthy controls.
|
21933670 |
2012 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the substitution of amino aa70 of Arg for Gln in patients infected with HCV-1b increases with age, and it is associated with severe liver disease accompanied by elevated AST and gamma-GTP levels, as well as the development of hepatocellular carcinoma.
|
19950230 |
2010 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Anti-Golgi antibody was positive during treatment coinciding with ALT/GGT flares but with hepatitis C virus (HCV)-RNA negativity, disappearing after stopping treatment, with normalization of ALT/AST levels.
|
17032416 |
2006 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, no correlation was observed between serum HCV RNA levels and the severity of liver disease as judged by the values of serum albumin (r = 0.175), bilirubin (r = 0.217), ALT (r = 0.06) and AST (r = 0.004) levels.
|
15285030 |
2004 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compared with placebo, none of the herbs showed effects on HCV RNA or liver enzyme, except for silybin, which showed a significant reduction of serum AST and gamma-glutamyltranspeptidase levels in one trial.
|
12650784 |
2003 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AST levels correlated with intrahepatic HCV load (r = 0.52; P = 0.001).
|
11992575 |
2002 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Multivariate analysis by ordinal logistic regression model was performed: age, gender, race, time on HD, allocation of the patients among the HD units, etiology of end-stage renal disease, HBsAg status, anti-HCV positivity, HCV genotype, and AST/ALT levels were independent factors, and viremic levels of HCV in serum were assumed as dependent variables.
|
9832642 |
1998 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
HAI was correlated with ALT, AST, and HCV-RNA levels, the latter determined by quantitative RT-PCR.
|
9753286 |
1998 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
HCV RNA positive patients showed serum AST (P < 0.008) and ALT levels (P < 0.0001) higher than HCV RNA negative patients.
|
9249775 |
1997 |
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased quasispecies heterogeneity correlated with the estimated duration of HCV infection (P < 0.05), parenteral-acquired HCV infection (vs. sporadic, P < 0.05), serum HCV RNA levels (P < 0.05), and HCV genotype 1 infection (P < 0.05), but not with age, serum AST, ALT, or Knodell score.
|
8818972 |
1996 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Traditional tests of liver function (ALT, AST, AP, and GGT) were of limited use in predicting HCV-RNA transmission.
|
8154029 |
1994 |
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fourteen of the 18 had elevated serum aminotransferase activities (AST/ALT) but so also did 9 other subjects who were seronegative for both HBsAg and anti-HCV.
|
7974663 |
1994 |